Latest Intelligence on Pain in South and Central America

Published within

« | 1 | » »|

Type Product title / description Pub Price
Expert View
Expert View

New advertising code of conduct established in Vioxx withdrawal fallout

Recent high-profile drug withdrawals have resulted in a new code of conduct to govern direct-to-consumer advertising. As more and more drugs are likely to come under regulatory and public scrutiny, the pharmaceutical industry will need to employ effective marketing and education strategies to ensure patient and physician confidence is retained and the impact of drug safety scares is minimized.

Published By Datamonitor
09 Mar 2006
ResearchWire
ResearchWire

Neuropathic pain: opportunities await despite generic threat

Published By Datamonitor
29 Sep 2006
ResearchWire
ResearchWire

Breakthrough pain market: high unmet need set to drive growth

Published By Datamonitor
17 Nov 2006
ResearchWire
ResearchWire

Neuropathic pain: market set to double over next decade

Published By Datamonitor
31 Oct 2007
Expert View
Expert View

Pfizer's novel NGF pain drug is potential game changer

Phase II clinical trials of tanezumab in osteoarthritis, chronic low back pain and interstitial cystitis have demonstrated the drug's analgesic efficacy across these three chronic pain settings. Despite safety concerns and a high price point, Datamonitor expects tanezumab to enjoy a significant first-in-class advantage in a potentially lucrative novel area of pain therapy.

Published By Datamonitor
08 Feb 2010
Expert View
Expert View

APS 2010: opioid safety and tolerability analyses take center stage

Opioid-related announcements at this year's American Pain Society meeting reflected the FDA's current focus on instituting regulations to increase the safety of this class. Johnson & Johnson used the meeting to present long-term data for its advanced candidate tapentadol, while King Pharmaceuticals demonstrated a taper procedure to be successful in minimizing withdrawal in patients taking Embeda.

Published By Datamonitor
17 May 2010
Expert View
Expert View

APS 2010: fibromyalgia newcomer seeks differentiation while prospective player draws nearer

Established drugs such as Cymbalta and Lyrica will serve to restrict uptake of the most recent entrant to the fibromyalgia market, Savella. Accordingly, data presented at this year's American Pain Society Annual Meeting indicate that Savella's marketing companies are endeavoring to differentiate the product from its key competitors in order to maintain uptake and drive sales.

Published By Datamonitor
17 May 2010

« | 1 | » »|

No help is available.